Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 44 HER2-positive Breast Cancer 8 Carcinoma, Non-Small-Cell Lung 5 Breast Diseases 3 Brain Neoplasms 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2 Positive Metastatic Breast Cancer 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Estrogen Receptor-positive Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Cancer Invasive 1

Interventions

Tamoxifen 2 Paclitaxel 2 pyrotinib 1 pembrolizumab 1 palbociclib 1 iniparib 1 darolutamide 1 Thioctic Acid 1 Pentoxifylline 1 Metformin 1 Letrozole 1 Doxorubicin 1 Cyclophosphamide 1 Capecitabine 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Female × pyrotinib × Clear all

NCT04126525 2025-09-11

NeoATP

RenJi Hospital

Phase 2 Active not recruiting

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡